SCHEMBL17713301

SCHEMBL17713301

N#CC(N)CCc1ccc(Br)c(F)c1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.32
▸ KCNH2 Q12809 2/20 0.32
▸ KDM1B Q8NB78 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17713409 0.76 TAAR1 (0.47) —
SCHEMBL17713434 0.75 DPP4 (0.37) —
SCHEMBL19899969 0.75 MEN1 (0.52) KDM1AKCNH2KDM1B
SCHEMBL27410802 0.74 GRIK1 (0.52) —
SCHEMBL1128476 0.74 TAAR1 (0.52) —
SCHEMBL17713426 0.72 NAAA (0.36) —
SCHEMBL17713491 0.72 DPP4 (0.40) —
SCHEMBL17713492 0.72 PYCR1 (0.39) KDM1AKDM1B
SCHEMBL17275650 0.71 CYP1A2 (0.33) KDM1AKCNH2KDM1B
SCHEMBL29392470 0.71 PTPRC (0.41) KDM1AKCNH2KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9901571-B2 Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists RAQUALIA PHARMA INC. (JP) 2018-02-27 — — US disclosed
US-20170304277-A1 TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2017-10-26 — — US disclosed
EP-3212648-A1 TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RaQualia Pharma Inc. (JP) 2017-09-06 — — EP disclosed
CN-106795158-A Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists 拉夸里亚创药株式会社 2017-05-31 — — CN disclosed
WO-2016067638-A1 TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2016-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304277-A1 TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS GHSR, GHRHR, GIPR KDM1A 1703/4885KCNH2 719/4885KDM1B 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback